J&J acquiring Novira

Johnson & Johnson (NYSE:JNJ) will acquire HBV play Novira Therapeutics Inc. (Doylestown, Pa.) for an undisclosed sum.

Novira's lead candidate NVR 3-778 ( NVR-1221) is in Phase I testing to treat chronic HBV infection. The compound is an oral small molecule inhibitor of the HBV core protein. ...